UNSPSC 51142021: Bicifadine

This classification denotes an analgesic agent with the molecular formula C12H15N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B0SV3N7J3H, chemically known as 3-azabicyclo(3.1.0)hexane, 1-(4-methylphenyl)-, (+-)- but generally known as bicifadine, which bears US NIH Compound Identifier 47953. Bicifadine most often comes in base and hydrochloride forms. European Medicines Agency schedules Bicifadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05818MIG.

UNSPSC 51142021 Bicifadine, a Commodity code, does not map clearly to the state and local opportunities presented in the source. The code nominally refers to a specific pharmaceutical active ingredient, but recent solicitations tagged under this code include naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements—none of which center on bicifadine. The mismatch suggests either a cataloging inconsistency in the source data or that this code is being used as a catch-all for broader pharmaceutical procurement when more specific commodity codes may be unavailable. State and local buyers under this classification span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, covering Minnesota and Oregon participants).

Recent activity shows three distinct procurement approaches: Seminole County is seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB posted June 30, 2026, with response due July 26, 2023; Texas HHS Commission issued an RFI in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels; and MMCAP released an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers, with proposals due March 26, 2026. Geographic spread centers on Florida, Texas, and the upper Midwest (Minnesota and Oregon), with procurement mechanisms ranging from traditional competitive bidding to exploratory RFIs and cooperative purchasing vehicles. Vendors pursuing opportunities under this code should verify the actual commodity scope against the specific solicitation to confirm alignment, as the code's nominal definition does not consistently match posted requirements.